Anavex Life Sciences Corporation
AVXL
Get informed when a big investor buys or sells
+ FollowMarket Cap$242.8M
Close$
$1.20
53.7% downside
Current Fair Value
53.7% downsideOvervalued by 53.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $242.80 Million |
|---|---|
| Enterprise Value | $124.47 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.54 |
| Beta | 1.14 |
| Outstanding Shares | 91,453,995 |
Return
| Return on Equity | -21.38% |
|---|---|
| Return on Assets | -20.01% |
| Return on Invested Capital | -23.37% |
Valuation & Multiples
| P/E Ratio | -10.02 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 2.6 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -4.74 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 28, 2026
EPS Estimate
$-0.08
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 24, 2026
EPS Estimate
$-0.11
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2910▲ 8.23% |
|---|---|
| Total Calls | 823,100▼ 55.84% |
| Total Puts | 239,500▼ 38.42% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 41.22%▼ 1.93% |
|---|---|
| Total Invested | $97.73M▼ 20.36% |
| Investors Holding | 187▼ 12.00% |
ESG Score
No data
About Anavex Life Sciences Corporation
CEO: Christopher Missling Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, ...